Neuroendocrine Prostate Cancer Treatment Options
Featuring: Amit Gattani, Patient; Dr. Rana McKay, UCSD; Dr. Emmanuel Antonarakis; Ally Perlina, CureMatch
In short
Amit Gattani, a 53-year-old with stage 4 metastatic prostate cancer, shares his experience navigating eight lines of treatment over four years, including a recent shift to 20% neuroendocrine disease, bone marrow involvement, and new neurological symptoms from tumor pressing on cranial nerves. His situation shows how quickly things can change and how other patients, peer communities, and multiple specialist consultations can help someone map out next steps when standard treatments stop holding.
- •If your cancer has shifted toward a neuroendocrine type, ask your oncologist specifically whether that changes which treatments or trials you qualify for — it may open different options than adenocarcinoma alone.
- •New neurological symptoms like facial numbness or double vision in a metastatic cancer patient can signal tumor pressing on cranial nerves; bring these up with your care team right away, as imaging and a neurology consult may be urgent.
- •Liquid biopsy results from different labs (such as Guardant and Tempus) can show low consistency with each other — if your results seem contradictory, ask your oncologist how much weight to give each report before making treatment decisions.
- •Building a coordinated panel of specialists — a primary oncologist, an academic GU oncologist, and outside consultants — can give you more angles on a complex case and help you feel more confident in your treatment roadmap.
Watch on Cancer Patient Lab YouTube
Ask anything about this — free, no signup
Instant answers grounded in real guidelines, not the internet.
Brad Power April 19, 2023 “If there is something related to neuroendocrine control, that is what is of most interest.” – Amit Gattani
Meeting Summary
Some advanced cancer patients find that they don't get durable responses from any treatments, and their condition continues to deteriorate. They need to identify new treatment options while also dealing with side effects, weakening health, and blows to their resiliency. Things get even more urgent when the tumors start pressing on organs, and the cancer mutates to an even more aggressive form. Consider the case of Amit Gattani.
Amit is a stage 4 (metastatic) prostate cancer patient, who has been battling the disease for over four years. He is 53, and was diagnosed when he was 49. He is on his eighth line of treatment (including an immunotherapy trial) in the four years, and he has not found anything that has substantially reduced his aggressive disease. His PSA is in the 450-500 range. His metastatic lesions are all in his bones, which are painful and hard to biopsy.
Each treatment provides minor control/stabilization for about six months or so, and then he needs to change his treatment. Recent additional findings include mutation of his cancer from pure adenocarcinoma to 20% neuroendocrine (a very aggressive cancer), and that cancer has also infiltrated the bone marrow, creating even more myelosuppression.
Professionally, Amit is a computer engineer with over 25 years in the semiconductor industry – about half in engineering roles and half in business leadership roles. He has a background in business, strategy, and marketing. He took off work a year ago to focus on his family and health. He has two kids in college, a daughter and a son. His wife is a physician, and many of his friends are medical experts.
Amit is looking for a treatment roadmap with the help of this community. , PCF on Facebook, and ZeroCancer. In this session, Amit reviewed his recent experience and looked for feedback on what he should do next.
•He started to feel numbness on the left side of his face, initially in the jaw area and then eventually moving to his left cheek and eye.
•His neurologist suspected compression of the fifth cranial/trigeminal nerve. (This is the largest of the cranial nerves. Its primary function is to provide sensory innervation to the face.) An MRI confirmed it. The tumor is pushing the dura (the thick membrane that surrounds the brain and spinal cord), creating multiple cranial nerve palsies (complete or partial weakness or paralysis of the areas innervated by the affected nerve). He started high dose dexamethasone (a strong corticosteroid) to manage the inflammation and is in active discussion with radiation oncology for a treatment plan.
•He started to have double vision at distance starting mid-April.
•MRI shows early signs of Meningeal Carcinomatosis (compression of meningeal lining between skull and brain), likely due to neuroendocrine cancer growth.
•He got another blood transfusion to help with cell counts (his second transfusion in April).
•He has been off treatment/chemotherapy for five weeks due to low cell counts. He is hoping to get back to treatment this week. Amit also brought to the session recent results from conversations with his medical advisors:
•Radiation decision
•Meeting with Dr. Rana McKay of UCSD on a consultation, especially related to BAT.
•A consultation with Dr. Emmanuel Antonarakis, also on BAT.
•Review with Ally Perlina of CureMatch on his new CureMatch report (drug combination recommendations targeted at his biomarkers) Patients who are actively engaged in their care are more likely to get better outcomes. They need specific, personalized information about testing and treatment options, which can come from a community of fellow patients and hackathons. While the group discussion may not come up with any breakthrough ideas, we hope Amit will get more confidence in his strategy and next steps from a conversation with our community. Testi Testing Results The surprising thing is that there's a very low consistency between Guardant and Tempus. That makes this decision-making really challenging. Amit’s Request Any advice on how to control the rise of his neuroendocrine cancer? The information and opinions expressed on this website or platform, or during discussions and presentations (both verbal and written) are not intended as health care recommendations or medical advice by Cancer Patient Lab/Prostate Cancer Lab, its principals, presenters, participants, or representatives for any medical treatment, product, or course of action. You should always consult a doctor about your specific situation before pursuing any health care program, treatment, product or other course of action that might affect your health. Meeting Notes The information and opinions expressed on this website or platform, or during discussions and presentations (both verbal and written) are not intended as health care recommendations or medical advice by Prostate Cancer Lab, its principals, presenters, participants, or representatives for any medical treatment, product, or course of action. You should always consult a doctor about your specific situation before pursuing any health care program, treatment, product or other course of action that might affect your health. Discussion Outline 1. Introductions. 2. Journey of treatment and recovery. (5:13) 3. The endocrine component of cancer. (9:22) 4. What is the medical panel most worried about? (13:37) 5. Options for treatment. (21:43) 6. Olaparib vs. Carboplatin. (26:04) 7. Variants of unknown significance and their value. (31:05) 8. What biomarkers do you think would work? (37:41) 9. Computational models of treatment options. (46:06) 10. Androgen deprivation therapies. (48:59) 11. Oral testosterone and PARP inhibitors. (56:40) SUMMARY KEYWORDS data, point, genomics, treatments, radiation, oncologist, missense, therapy, panel, area, chemo, life, unknown significance, target, benefit, endocrine, cdk, disease roadmap, part SPEAKERS Amit Gattani (70%), Rick Stanton (8%), Sheeno Thyparambil (6%), Brian McCloskey (4%), Russ Holyer (4%), Brad Power (4%), Jeff Krolick (2%), Richard Anders (2%) Brad Power As all of you probably know, we have two types of weekly webinar meetings. One type is the subject matter experts, like Geete Pedersen, who's on today. She talked about genomic expression. We query them and people get an opportunity to find out what their services are. And often they can get access. The other type of meeting we have is the type we're having today, which is where a patient reviews his case. Mike Yancey, Brian McCloskey, and Rick Stanton have done that. That gives us an opportunity to get feedback from the community. Often we find that patients have explored some of the same sorts of issues and can share their experience, what they learned, what worked, and what didn't work. Amit will be presenting his case and the questions that he has and then opening it up for comments and sharing experiences. Amit Gattani 1:12 This is a picture of the redwoods that I took about a year back in California. I thought it appropriate for the title. I'm a visual person. I take a lot of pictures. You guys know me, but I wanted to introduce you to who we are. This family photo was taken late last year. My wife is a physician. She's a hospitalist at Kaiser here in the Sacramento area, in Granite Bay. My daughter is 21 She's about to graduate in a month from NYU Tisch, in theater and film. One of my current goals is to be able to travel to her graduation, which, as you will see, is not a trivial thing right now for me. I want to be able to in at least three weeks from now be in New York to see her graduate. My son is a freshman at UCSC. He just started this year, so both kids are out of the hou house. This lovely dog Biscotti is an 11-year-old Labradoodle Australian lab. This other picture was taken a couple of years back when there was a massive bloom of flowers here in Folsom Lake. When the water levels are very low, then we get this kind of bloom here in Folsom Lake. This year, the water levels are high, so we don't have a bloom like that. He hangs out with me all the time. This is my medical panel. I've been working with Dr. Archana Arantharam at Kaiser. She's my full time oncologist. Dr. Jonathan Chou at UCSF is my other primary oncologist. Both were fellows of Dr. Eric Small at UCSF. They coordinate my care really well because they have known each other for a while. They work with Dr. Small and trained together. They are the primary caretakers of my decisions. Dr. Manish Kohli is a very well known academician and GU oncologist. He's currently at Huntsman Cancer Institute at Utah. He holds a bunch of academic chairs and stuff like that. He's always our go to consultant on the side. We know him personally very, very well. I can call him on a Sunday morning, he'll spend an hour with me on the phone, and we'll just walk through things. He's very well connected in the industry. So he connects me to many other people as needed. He's the one who made the connection to Dr. Antonarakis. He's always available for consultation. I’ve also been working with an integrative oncologist for a couple of years at UCSF. They try to help with all non-traditional methods and manners. It's been a good, interesting journey to work with them. I wouldn't say anything fundamentally different has come out of it, but it's always good to have an integrative oncologist. That's my primary team. We have talked to many experts in the past. I haven't listed them all here, but I did do recent extensions. We had a consultation with Dr. Rana McKay last week. This was related to the BAT discussion tha that has been hot and going on here. With Dr. Emanuel, after connecting from Dr. Kholi and seeing my full history that I shared with him, he decided to directly call Dr. Chou at UCSF to discuss my case. He offered to see me in person at his clinic in Minnesota and then assess/discuss if BAT is an option. So that lead is open for me… I have to decide when that makes sense in the current scheme of things… but the signal back to me was not that BAT is a slam-dunk and let’s do this. Actually since that conversation just 2-weeks back, my cranial nerve compression issue got worse causing my vision issues. This has been my journey to date. Most of you guys have probably seen this thing, as data with the intel we are, we try to track everything vs. PSA. At one point, I needed a log scale, because the PSA was going from 200 to 2.2, and stuff like that, but I'm way past that. I'm running into the four hundreds now for the past 18 months. So considering the scale of a lot of this stuff is gonna run away starting in late 2018. I won't go through everything in detail. But you can see the treatments have gone through Chemos, Enza, Arbiterone, many focal radiation treatments, then went through the immunotherapy trial along with the lutetium, as a kind of primer really didn't work, you can see what happened. I'm in a therapy trial over here during that phase, then I started chemotherapy again (Docetaxel rechallenge), it helped bring some control back. And for over 18 months I was closely tracking Lutetium treatment availability around the world as it seemed like a great targeted option and I was very PSMA sensitive. I was willing to travel the world to get close to treatment, if it didn't become available over here. When it did become available, we switched to Pluvicto over here after the chemo. I just had three doses of that treatment before we needed to stop it due to excessive myelosuppression. It's unclear what it did or didn't do over there. Things have just been kind of moving along with it. And I'm back on this is live right now on chemo. And I'll talk about why and where we are. But I want to kind of point out radiation stuff around this time. I have had focal radiation to take care of certain focal things over here. Last July is when I started to have massive spinal issues in my lower back. And that's when the high dose radiation and stuff has started, and we'll talk about how that whole journey has gone and a little bit. The big stuff and findings in the past three months. At the beginning of the year things were starting to look okay. I'm done with Pluvicto. We don't know what's next. At least I was symptom-free and everything else. But it didn't last long. In February, I started to have very serious pain in my thoracic spine. Last July was lumbar spine this time, it was thoracic spine, massive nerve compression. From being on vacation in India, in a week or 10 days, I couldn't even walk. It was pretty bad. I had to get radiation treatment to take care of that, which it did. But it left some nerve compression issues that have persisted. After that my walking has been unstable, because I lost some nerve sensors in my feet that haven't fully recovered yet. At the same time, the PSMA scan indicated that now the disease has infiltrated the bone marrow quite extensively. So the disease that was in the bone, and we knew it was in the vertebrae, it started to go on both sides. On one side, it started to get into the spinal channels. On the other side, it started to get in the bone marrow. So that reduced significant bone marrow capacity for me and other treatments didn't contribute obviously because everything suppresses. Another finding that happened simultaneously was that my biopsy showed that I'm not pure adenocarcinoma anymore. There was a 20% neuroendocrine component involved in my cancer. So now we're not just dealing with prostate cancer, we are dealing with a neuroendocrine component as well. And my medical panel is most worried about that part. Also, at this point, they believe that all the stuff that we've done with the prostate and everything else tried to manage and contain some of that, but it has given the chance for something else to grow and controlling that is the hardest part at this point. I was recovering from all of this stuff from February to March trying to kind of rationalize my new normality and in April, about two-and-a-half weeks back, I started to get numbness on my face. The left side of my face is very numb, and it has been progressing. You may not be able to tell by my expression, but I'm actually pretty frozen on the left side of my face. But what happened last weekend was that my vision got messed up. At my computer screen level, I can see okay, but at a distance I'm seeing double vision. Each eye is okay. But the nerve pressure or the stuff that has built up in there has changed the ophthalmic stuff that I cannot actually see properly now. So now I cannot drive. My walking, which was already impaired, now is further impaired because you know, taking steps and visual stuff is kind of a messed up. Anything over five feet away and beyond, I'm having difficulty seeing clearly. I put on an eyepatch as needed and try to look like a pirate whenever I feel like, but that's all. Amit Gattani 11:14 I'm managing. The MRI shows compression of various cranial nerves in the base of my skull. Besides the cranial, and I'll show you the MRI, the disease that they're calling is meningeal carcinomatosis. This can go to the brain at this point is kind of the concern, right? So the quality of life, as you can see, is suddenly drastically shifted and changed in what I'm able to do or not do. And that's obviously going to be where things are. The medical panel's concern is that mutation has spread diseases out of control with no prophylactic pathways at this point. And it can spread to other organs. It is very hard to predict now. Many diseases that cause pain will know how to manage pain radiate smartly, but this is out of the box now. And we just don't know. So I count every day as a good day, and you just don't know what tomorrow might or might not be. So here's kind of what's happening in sharing some of the MRIs also. So I had an MRI, beginning of March, same MRI. And that was okay, that was non actionable. Within four weeks, and this MRI is from April 14, within four weeks, you can see the growth of the disease, this is the skull base and the kind of meckel's cave area that's called on my right side, you there is kind of the compression, but it's still okay, on the left side, which is where my face is frozen, you can see the difference between the right and left side and measurements, if you can tell, right, so there's a there's a pretty big compression over here, that is causing my facial stuff to, to kind of get all these nose suppressed. There's a growth in temporal lobe area also, it's not marked as supposedly it's not causing any symptoms. But it may be hard to tell that there is the skull and brain lining. Right. So between the brain and the skull, the dura that is there, has white caking at this point. That is the meningeal core stuff that has everybody most worried right now. The plan is I'm starting radiation today. My appointment for radiation is at 11 o'clock today. I'm starting radiation to address this area. This area is not going to be addressed right now. And this area is not going to be addressed right now. Because it is actually unclear if addressing this area will benefit or cause more cognitive damage and bone marrow reduction also. So it's just wait and watch and see where things go and, and try to kind of deal with that. But what has my medical panel most worried about is more of this kind of stuff. Things are getting kind of getting in the dura and what will they do in the press against the brain and loss of cognitive function. These are some of the older MRIs since we're talking about kind of how the spinal stuff has happened. This was July 2022. This is my lumbar spine. You can see my L1 L2 area was completely compressed, so disabled me. Radiation helped me get out of that mess. And really kind of made me functional again. This is February of 2023. This time it was thoracic spine. This area is completely blocked off. So moved from lumbar, thoracic to now kind of the head and the skull base. So that has been kind of how the cancer has moved from bone to spinal cords and stuff. And part of the this is that the adult bone marrow factory or the large capacity areas or pelvic bones, which are irradiated heavily along with the lumbar spine, my pelvic bones were irradiated in July 2022 along with the spine, spine again in February 2023, and I'm starting now this bones is another area where good reserves of marrow factories are. Skull which is possible future radiation which again the concern is that will reduce small myelosuppression so while I'm dealing with all of these and all the radiation fixes have been good to get me functional, the effect of radiation on bone marrow suppression has been actually meaningful. And now bone marrow is my limiting factor for treatments because my cell counts are very very low. And everything else suppresses cell counts further so that has become a limiter to what my treatment looks like. I've included this for data because we love data, but I won't go through it in detail. For almost three-and-a-half to four years I was keeping well with the treatment o about My Neuroendocrine Cancer?” I've included this for data because we love data, but I won't go through it in detail. For almost three-and-a-half to four years I was keeping well with the treatments. I was tolerating them well. I was dealing with them. They weren't working, but I didn't have a tolerance issue with treatments and stuff like that. You can see hemoglobin was not great, but at least have hovered around in a respectable stage. July when I said the big radiation treatment happened and then Pluvicto stuff happened between July and September. That's when my hemoglobin started to tank, and since then it has been okay. Let's do something to prop up. These are my blood transfusions that I have gotten over the past months to try and kind of prop up as you can see just about the beginning of April, I was at 6.4. Two blood transfusions later it has kind of propped me up and you can see in the WBC and RBC counts also moved up. Platelets really are the chemo limiter. My platelets dropped at the beginning of April. I started this chemo. The regimen left for me at this point was just to try and do chemo. and I'll kind of get into the details of why that is specific chemo. But the consensus was carboplatin plus cabazitaxel is the chemo that we need to give it a try. It's not targeted therapy, we need a nuclear option and try and see if that can help contain it. Carboplatin is very toxic, but you know, we had to take a chance with that and we started with that on March 1 with a smaller dose. So, generally they are three weeks cycle dosage, I was only given what is small dose on a weekly cycle just to see what happens. After two carbo and a third small dose with was cabazi, you can see how my platelets drop to almost kind of 60k level. You know safe level is about 100k before people try to treat you and platelets are not something you can prop up very easily or in a is sustained manner. Platelets are the chemo limiter. So then I was on a five-week break to get next chemo that I got last week. I mean of course I got two blood transfusions to transfusions, and platelets did recover by themselves, which is actually good news. And then I did get another cycle of chemo last week and I don't have data for that. This panel is my treatment limiter right now in terms of I don't qualify for the trials for the reasons that my hemoglobin/CBC panel is very, very low. The fact that I have neuroendocrine differentiation rejected from all the trials at this point as well. So experimental stuff is out of near term pathway, you know, of course we can talk about off road therapies and things like that, but no systemic trials that I was kind of on the books for for a while at UCSF are real near term options. So here is where I am treatment wise. As I said chemo, Carboplatin and Cabazitaxel are kind of the go to options from The Medical panel. Carbo because it actually targets neuroendocrine and also targets CDK12 mutation which has been one of my primary drivers. It has some PARP inhibitor benefits, which is a secondary to all of that. And then Cabazi is the remaining taxel to prime address the prostate cancer part of it. They've been trying to get to a doublet therapy to combine both of those things, but it is too toxic. And we have not been able to combine. I'm actively on this treatment, I would say, limited to small doses delivered in the last two months, balancing, so we look at things where things are those decisions when to give all that is made on a weekly basis, just based on where things are. Effect of the chemo treatments so far, hard to know. The PSA has come down from 490 to 476. After the three doses, so, okay, 15 points drop on a 500. We don't know how good that is, and at this point, my team is not exclusively focused on PSA vs. symptoms and also due to the neuroendocrine component. Amit Gattani 21:12 PSA is interesting. And we'll keep tracking it. But that's not the only indicator for me at this point. It's about everything else. “What Should I Do about My Neuroendocr The primary path was, “What mileage can we get out of this? And how much can I tolerate this?” As I said, radiation, obviously, if I can unfreeze my face and fix my vision issue, those are huge quality of life issues for me right now. Starting today, there'll be 10 radiation settings to try and address that. So we'll see how that goes. To radiate brain/full skull to address compression and the on meningeal lining is a possible roadmap item. I have very debatable data from various panel members about whether to do it or not. It's not a decision that needs to be made right now. But it will be if and when it comes, we'll have to figure out if that will make sense. If I am not able to tolerate these chemos, there are a couple of other chemo options. There's topotecan, which has nothing to do with prostate cancer. It's all post plantin and neuroendocrine thing. Our data comes from small cell lung cancer may not be very relevant. It's a possible roadmap item. I'm at a stage where there's not too much we can worry about because things change so fast and quickly that okay, yeah, it's there. When we have to make a decision, then we'll figure out whether that choice is still the relevant choice or not. And then another chemo which is a kind of a Hail Mary for preventing organ metastases, again, very speculative, possibly a roadmap item at some point, a kind of thing. So none of these actually are prostate-cancer-related drugs, they are all primed to prevent neuroendocrine growth in other parts of the body. It's a pretty limited and short list over here. I have some reject options over here. I'm sure they will be of more interest to this panel. Olaprib has always been on my roadmap because they target CDK12 while it's on hold at this point, because it's even more toxic than carboplatin. So carboplatin is kind of supposedly a poor man's olaparib. And if I cannot tolerate carboplatin, then olaparib is a dead thing for me. And Carbo has a little bit more benefit at this point with neuroendocrine than olaparib doing the CDK12 mutation. It was always a roadmap item. We never got to it. But at this point, it's like, “This is going to be way too toxic for me to even consider.” I know BAT has been a big discussion, and as said, because it's a non-bone-marrow-suppressive option. It has been rejected universally by my panel, including Dr. Rana Mackey, who I consulted specifically for this. The reason is that at this point, their concern is the cancer is way too aggressive, and flare ups. While for most people it can be transitory, it may be too hard to control and their permanent damage may create paralytic damage that could be very unpleasant. So they just don't think this is in the zone where this is even worth the risk at this point, as I said, all three of my oncologists rejected it. Dr. Rana McKay was not supportive right from the very first time I asked her about BAT. Dr. Antonarakis is willing to say, “Come up to my clinic in Minnesota, and we'll review the case and then see where to go.” I have to decide when and whether that will make sense or not, but the offer is open for him to meet with me in person in Minneapolis in Minnesota. And prior to let him judge that. But I've put that on the backburner for now. Russ Holyer 26:13 On olaparib. Who told you it's toxic? I’m curious where that came from. My medical oncologist says it's not toxic at all. It seems like there's a little toxicity and a few side effects. It's more toxic than chemo? Amit Gattani 26:33 It’s more toxic than carboplatin. Multiple oncologists have told me that: my medical panel oncologists, Jonathan Chou, Manish Kohli, all of them believe it. Russ Holyer 26:52 Okay, so they all say the same thing. Is it more toxic in your case? Or is it because of your white blood cells or some parameters? Amit Gattani 27:02 It's for all lines of cell count, my driving concern. The various trials based on genomics, and everything else we had targeted by specific antibodies (various ARV targets, Steap1/Amgen509 Bispecific Antibody, CAR-T, etc.), are all off the table. These are some of the other drugs (Etoposide, Azacitdine - from CureMatch, Sabizadulin, Cabezantinine, nPlate) that have come up. There is not enough evidence, data, ROI to focus on that. There are a few open items (Everolimus, Abemaciclib, Trastuzumab) from CureMatch, based on some of the esoteric data of a few genes here and there. But, and I'll get into genomics on the next page a little bit, as you know, that stuff is very low priority for my oncology team. You can find something like, “There's a small gene here that has this stuff.” But they're focused on the bigger picture of what's happening rather than, “What if I address that specific gene, which is a very small expression at this point, and we don't know whether that is a driver or not a driver?” I had a very good conversation with Ally Perlina of CureMatch last week. I'm keeping them on the list, but as I work with my medical panel, these options are interesting, but not actionable, or where we can focus, because doing something always has an opportunity cost of not doing something else. They have to make that call bedside on what they can deliver. So that's a pretty short list of things. My real path right now is the chemo: carboplatin plus cabazitaxel. This is systemic therapy at this point. And radiation is for symptom relief. Beyond that, everything is just like, we don't even know what may happen or not happen. I'll cover a few pages on genomics, and then open for discussion. I've been using Guardant as a reference point almost periodically. All these reports are on the Google Drive, if anybody wants to take a look at that. CDK12 has been a driver mutation. We've been tracking it. It's been there. That's why olaparib was always on the treatment options list, because it targets that. Olaparib has very good data on CDK12. It's the only FDA-approved drug that has some data, but that evidence was actually very, very weak. There seems like they snuck it under at the last moment of, “Oh yeah, this can help.” It has been, “Okay. Interesting. We'll look at it.” But it was not a massive belief on the evidence of data. AR amplification has been high. So that's why the BAT was always interesting. Other stuff has been relatively low and kind of gone from being there to ND levels. You can see how things have graphed. BRCA2 was not there the first time. In the last report, something kind of showed up. The carboplatin helps with BRCA2. So carboplatin is now a little bit of a more multifaceted approach for me. That has been my Guardant history. [ Just for a reference point, I did the Tempus xF+ panel, because we are talking about all of this. The surprising thing is that there's a very low set of consistency between Guardant and Tempus. That makes this decision-making really challenging. CDK12? Yes, both of them have it. It's there. It's relevant. We can debate what the allele frequency is, but we have known CDK12 was the driver, right? Everything else there was, like, you know, is almost mutually exclusive between Tempus and Guardant. Right. So there is some DNMT3A here, which wasn't in Guardant. There's MTOR, which, again, they listed as variants of unknown significance. So they say it's not actionable. But MTOR is very high in case of Tempus, you look at Guardant and it's ND level, it was there a little bit and now, ND. So, my key thing is that they will lose sight of consistent data points with which my medical team is like, Okay, let's go make a decision to target this. Everything else is like, Okay, interesting. But without consistent and validated da data, it's like, you know, what are we trying to choose here? Yeah, we can include some MTOr stuff or ERCC6 stuff, but you're also calling it variants of unknown significance. Other reports don't show it. You know, so it all goes back to how good is this data? The industry at least feels like the alignment between industry and the medical practitioners on how good the data is, and how to actually effectively use it when things don't match up across. That alignment with Genomics is not there, and people don't have time to actually keep chasing small stuff right now. Here's a proteomics analysis that was done on tissue. It didn't really produce anything meaningfully actionable. I won't go through the details. AR amplification, AR proteins are high. We know that right? There's a top three protein, they say maybe there is some likely benefit, but it's non-detectable. So it's their non-detectable level, but maybe something can be done about it. They put carboplatin for ERCC1 protein in an unlikely benefit because of some resistance marker. I have shown this report to all my oncologists. It's like I don't know what to do with that. I think carboplatin has a good benefit for you, and we're going to stay with that based on experience. That's kind of their experience with that stuff. Right now. So what it comes down to is that it's interesting data, but it hasn't become meaningfully actionable for my panel to say, “Okay, really, really, this is cool.” It gives me an action plan, and I'm going to tap on the system. That's the unfortunate reality of all the cancer genomic stuff that I'm dealing with. So you said carboplatin becomes kind of the its neuroendocrine CDK12 has some PARP inhibitor benefit and that has become a “Hey, if I can tolerate and take carboplatin, that is likely a good option for me,” along with the capacity to learn if I can get to this doublet, which so far hasn't happened. “What I'm getting regular setbacks as you can see. In March I was struggling, I was thinking of EWOT and as a way to strengthen my physical body, doing physio, and everything else. Now I have a significant setback in my body and weakness, as well as the ability to walk many steps. I'm still trying to figure out how to keep recovering from that while going through the treatment. The roadmap has limited me frankly. The conversations are palliative at this point. “Hey, we can keep throwing toxicity at you.” But at some point, there isn't much left here to throw at you. And you just have to make a decision where the deadline is. Genomics: I've already talked about managing quality of life. And what's my best quality of life path is obviously a priority for me, because without quality of life, life is kind of what what is life, right? So that's kind of where I am physically, medically and mentally. We are starting radiation. Hopefully, that will help unfreeze my left part of the face and give me my vision back because without vision, all the joy of travel and all the joy of meeting people gets significantly impacted. I'm very focused now internally, to try and do what are the most important things in my life at this point, because I really don't know what tomorrow is or isn't. And the main stuff coming to the brain and paralysis, nothing I can do about those concerns, at least, again, we can try and radiate the skull, but it's not a simple slam dunk thing that it might or might not do. So that's pretty much it. Rick Stanton 38:01 Did your Pluvicto treatment help? Amit Gattani 38:04 I had PSMA scans before and after, and the intensity of focal areas of my disease seemed to have distributed/diminished a little bit. So things that were as dark were not as dark. So it probably helped in some areas. But it didn't contain the PSA, it didn't contain the spread of the disease to other diseases and stuff like that. It didn't give me an extension of life. It probably caused more bone marrow suppression also in the process. Rick Stanton 38:32 Okay, so you've had a fair bit of SBRT, right? Would proton radiation have been less harmful or less side effects? Amit Gattani 38:44 So haven't been just SBRT, it’s VMAT variant also, which is a volume metric modulated arc therapy also, VMAT was needed because of how bulky my spinal areas were, and how they needed to be treated. So, so far, touchwood radiation has always been very effective for me, so I can't say what the proton would have been even better. I will think about it. But so far, radiation has really helped me get out of the pickle. Rick Stanton 39:21 I wonder if the MTOR missense can offer a therapeutic target. It might be helpful to get a CADD (Combined Annotation Dependent Depletion) score for the missense. Combined Annotation-Dependent Depletion (CADD) is a widely used measure of variant deleteriousness that can effectively prioritize causal variants in genetic analyses, particularly highly penetrant contributors to severe Mendelian disorders. CADD is an integrative annotation built from more than 60 genomic features, and can score human single nucleotide variants and short insertion and deletions anywhere in the reference assembly. CADD: predicting the deleteriousness of variants throughout the human genome https://academic.oup.com/nar/article/47/D1/D886/5146191 Richard Anders 40:56 It seems like the problem is there are two conflicting liquid biopsies so you don’t really even have a clear signal. Amit Gattani 42:37 When they report this is unknown significance? What is that saying? Okay, they measure it, but they're saying it's of unknown significance. Rick Stanton 42:48 Unknown significance can possibly be further refined via the CADD score. Richard Anders 44:05 Maybe one thi thing you could do, which would take time and would probably be expensive and perhaps not worth it, is to make a PDX model with some tumor cells if they were available, and then test it with the mTOR inhibitors. With some of these variants of unknown significance, you don't know what – if anything – they affect. You know that they're a mutation, you know that they're not the same as wild type, but you don't know if the drug will interact with them or in fact how or whether they are even active at all. Brad Power 44:51 That was Brian's question too, about getting an organoid or doing some functional testing. Richard Anders 44:58 That will tell you if the mTOR inhibitor knocked down the mTOR mutant, but it wouldn't tell you if the mTOR mutant was actually driving anything. Amit Gattani 45:13 Yeah. Okay, I hear you. So getting an organoid test, which I kind of saw somebody did recently, requires live tissue taken live post biopsy. And I don't have an opportunity at this moment to get another live tissue biopsy that can be presented to the lab within 48 hours of being taken out. I'm going to get a solid biopsy done from Tempus on the tissue that's already there. It's a work in progress, and we will see what comes back from the solid biopsy from Tempus on that particular thing. The question I get from my panel is, “That is interesting, but is that the biggest area that we need to focus on right now?” And the answer always comes back from everybody, “No”. I am just being honest. Brian McCloskey 46:06 You're talking about your panel of doctors. It doesn't have to be a monolithic effort. We can deploy other resources to support what they're doing. I wasn't using an organoid, or building an organoid. I knew it was going to be difficult, just because of the tissue challenge that you have. So I wasn't putting all my eggs in that basket. But I'm wondering if there are some computational models just based upon the sequencing that you've done that could help us understand the menu of treatment options. What do we think is going to work and which ones don't we think are going to work? I don't know if you know, we've got Alex Feltus at Clemson who can run a data hackathon. I don't know if Pete Kane could potentially help in this effort. But it seems to me like you've got data, you've got some treatment options on the map. Can we at least be smarter about which ones we think are going to work? And aren't going to work? Amit Gattani 47:27 Yeah, so I'm open to what we can do with this data right in parallel. So adding multiple therapies right now is just very difficult, because I'm not tolerating a single therapy right now. Adding multiple therapies is like, “Okay, yeah, we can.” But I first have to show that I'm able to tolerate or deal with chemotherapy, so that's kind of where the real time thing is, but putting it on analysis and roadmap? Absolutely. So maybe Brian, you and I can chat offline and see what could be done. Brian McCloskey 48:04 If we were to pursue computational models, I'm sure we would need raw data. Do you know if you have any raw data? Amit Gattani 48:15 Well, we did the xF+ Tempus panel just so that we can get raw data, I haven't asked for it. And then I'll have the solid biopsy stuff kind of going on and then get the raw data from that as well. Brian McCloskey 48:32 Are you going to do the solid biopsy with Foundation Medicine? Amit Gattani 48:37 No, it's Tempus. Brian McCloskey 48:39 Okay. The xF+ test is about 500 genes. So the raw data may be maybe a little bit limited on that front, but the tissue hopefully could potentially open up more doors. Sheeno Thyparambil 48:59 A question with regards to your AR levels: I probably missed this. But what about your androgen deprivation therapies? I mean, have you had any of those? Amit Gattani 49:14 Yeah, I became refractory to those pretty early on. I mean, I went through Xtandi, Zytiga stuff way back in the early early days. You can see that I got a little bit of control, but never, it really never kind of held things back. Maybe it slowed things down. Sheeno Thyparambil 49:42 We observed that your AR levels are the second or third highest in our database. For comparison, Brian’s level was 911 or something like that, and yours is 3200 and change. You have extremely high AR levels. That’s borne out by proteomics. That’s also borne out by Guardant Health Genomics testing as well. I feel like that’s the point of attack, and that’s something not experimental, but something that you could go with the conventional therapies. Amit Gattani 50:15 Cabazitaxel is the conventional therapy that will address this. Sheeno Thyparambil 50:22 No. Taxanes address the tubulins. Amit Gattani 50:26 Okay, that's true. Yeah. Sheeno Thyparambil 50:30 You’re looking at, you know, apalutamide, Enzalutamide. Brian McCloskey 50:36 Darolutamide. Arvinas ARV-110, or ARV-766. I forget which one. (Proteolysis targeting chimeras - “PROTACs” - are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for their application in the management of both solid and hematologic malignancies. Since its initial discovery, the technology of targeted protein degradation, especially in the form of PROTACs, has had significant advances. A number of PROTACs have entered a late stage of preclinical development. Several of them are either in phase 1/2 clinical trials or approaching approval for initial clinical evaluation. This article discusses the preclinical and clinical findings of PROTACs of clinically relevant protein targets in cancer.) Amit Gattani 50:51 We talked about doing the trial with rechallenge at some point but the data from my panel was that there's a very low probability that retargeting will help, but I'll bring that up again. Sheeno Thyparambil 51:13 Yeah, because your February biopsy had the highest levels of AR receptors that we have seen. That’s definitely something that we should put on the table. Brian McCloskey 51:27 I think he's going to have a conversation with Manuel Antonarakis about bipolar androgen therapy. And it can be risky, but with his high AR expression, he doesn't have to be 53. But it would seem that that would be a pretty good match. Sheeno Thyparambil 51:52 I’m not that conversant with it. But you know, Enzalutamide is one of the pieces in the BAT therapy, but also you’re turning on and turning off signals. You need to turn off the androgen receptor signaling and with the high levels of AR, conventional androgen deprivation therapies might be useful here. And, and this was from and I know you stopped Zytiga way back I guess. But you probably need to reintroduce androgen deprivation therapies. Amit Gattani 52:25 I've been on Lupron consistently. I'm on Eligard and Lupron. That hasn't gone away. Sheeno Thyparambil 52:39 That was one thing that stood out for me, your Androgen receptor levels are high with both us and now Guardant Health showing it. Amit Gattani 52:47 That's known. Lupron has been consistent – every three months. I should have been more clear about that. Brian McCloskey 53:01 Sheeno, do you have any targets for neuroendocrine disease? Sheeno Thyparambil 53:07 Yes, we do. Amit does have in his report, I was looking through it, does have some neuroendocrine markers, like chromogranin a CHGA, I think he does have it looking. Yeah, he has an extremely high CHGA. It’s definitely there. Chromogranin A, synaptophysin and CD 56. These are three markers classically used for diagnosing neuroendocrine tumors. So his levels of chromograninA is very high, like 7000 plus. Brian McCloskey 53:42 Are there treatments that target those expressions? Sheeno Thyparambil 53:50 There are (no drugs that) typically nothing to target those three biomarkers, they are more to say whether you have neuroendocrine tumor, and when you do have your neuroendocrine tumor, you switch to Etoposide / platinum, which you are getting, I believe you are on platinum therapy which is part of that cocktail, right. So yeah, I believe you are on platinum. Amit Gattani 54:14 So Etoposide is kind of part of the same Platon thing right. So it okay, I'm on platinum carboplatin stuff Sheeno Thyparambil 54:24 Well you’re on carboplatin, which is different from etoposide. Etoposide is targeting TOPO2A. I think Mike Yancey had switched to that regimen, Etoposide-platinum. So he might have more insight on that. Amit Gattani 54:41 So my understanding is that Etoposide is given as a doublet and not as a single agent, and it is given with Carboplatin, right? Yes. So if I'm so they're working with Carbo, if I can tolerate carbo and then add cabazii, then post that Etoposide may be an option on the table. But again, Etoposide is not a signal therapy is my understanding. Sheeno Thyparambil 55:08 You know, Physicians usually think in terms of cocktails when it comes to Chemo cocktails. So yeah, you’re on Carboplatin and cabazitaxel. Right. That is the cocktail you are on. Two cocktails – cabazitaxel and carboplatin or etoposide and carboplatin. Amit Gattani 55:31 cocktail, right? So right now the priority is Cabo plus cabazi. So that you could target both neuroendocrine and prostate. Going to carbo plus etoposide side would be nuero only targeting. Sheeno Thyparambil 55:47 Make sense from our report. Cabazitaxel is basically an anti tubulin inhibitor. So you don’t have the resistance marker for anti-tubulin which is what TUBB3 non-detected meant i bout My Neuroendocrine Cancer?” Make sense from our report. Cabazitaxel is basically an anti tubulin inhibitor. So you don’t have the resistance marker for anti-tubulin which is what TUBB3 non-detected meant in our report. You don’t have a resistance marker for anti-tubulin, So you should respond to cabazitaxel. But for me, the thing that really stood out was your AR was like number two or number three in our database. Russ Holyer 56:40 If you did entertain BAT, or you did it, I strongly advise using an oral testosterone undecanoate for one day, or Androgel even, because they have very short half lives. The oral testosterone has a half life of about two hours. So whatever you would see with it would be really quick and wash out fast. So if you ever did entertain BAT, one pulse of a quick acting formula will allow you to see how you're reacting. If you went that route, you’d need to talk to Denmeade or Antonarakis or another MO versed in BAT. About the PARP inhibitors: There are other PARP inhibitors that are not officially approved. For example, there's talazoparib. Talazoparib might have worse toxicity for your hematological parameters. In a study I read the other day, it had better benefits than olaparib. Then there's rucaparib. I don't know what it's side effect are like. Amit Gattani 58:21 Getting toxicity profile is a very, very difficult challenge that I've been struggling with. We need to rely on the oncologists to say that because I had this long discussion with Ally Perllna on that topic. Also if there's a way to really quantify the side effects in various ways of something. If you can send me in the chat the names that you said I'll keep adding them to the list. I've gone through many of those things in the past, and they kind of get kind of in the reject like we were just talking about the Etoposide that Sheeno brought up right again it's it's there possibly at some point again consider looking at but for the reasons that I explained it's not on the table right now. Amit Gattani 59:34 PARP inhibitors, other than CDK12 targeting, have not been a big target area for me so far. All of the doctors on my medical panel are worried about n neuroendocrine right now. What do I do with that? All that other stuff is very interesting, but I'm worried about where the neuroendocrine is going. That’s where the head is for everybody individually for all the four doctors that I'm working with. Regarding the PARP inhibitors and everything else, we can keep having long roadmaps of things, which is always a good thing to have. But I'm just saying practicality is if there is something related to neuroendocrine control, that is what is of most interest. Brian McCloskey 1:00:37 Sheeno mentioned etoposide for neuroendocrine. Did the doctors mention that? Amit Gattani 1:00:44 Yes. Etoposide has been part of the conversation. Jeff Krolick 1:01:21 I went with a more complementary approach for quality of life, looking at increased comfort and reduced pain. All acupuncturists are not equally skillful, or as knowledgeable with maybe some Chinese herbs. Both of those have some research track record for improving quality of life. “TENS” machines are often used to relieve chronic pain, as is a very similar system called “Frequency Specific Micro Current”. Physical therapists can do that, and it's quite effective in relieving many different types of pain and even generates a cell fuel ADP in a certain way that can actually benefit some cancers in terms of reducing the load a little bit. But I wouldn't go there for a treatment. These are really all quality of life, palliative care, kinds of things. Amit Gattani 1:02:52 I go to my acupuncturist twice a week. I've been kind of based on my integrative oncologist. I think it keeps me calm and probably helps me. It's hard to isolate the effect of that, but I am actively in acupuncture as well. I will look into your solution of the frequency-specific microcurrent stuff and see where that is appreciated.
Related prostate questions
- →In Brisbane how do I get it for my dad. Stage 3 prostate cancer 75 year old...
- →Rising after prostatectomy. What are my options
- →What is the best tool for diagnosing Neuro-Endocrine Prostate Cancer? Best regards. Alexander Lalov...
- →A prostate measured at 180 and PSA 11.5. I am 76 and have no health problems and feel great. To be sure this week I...
- →A prostate measured at 180 and PSA 11.5. I am 76 and have no health problems and feel great. I have no insurance and...
- →Ask cancer commons and tony magliocco of protean diagnostics
- →Hey, i'm reading the book "The new testosterone treatment" by Dr Edward Friedman.
- →On the Tiffany trial for prostate cancer. Talk about that
Want to learn more about your specific case?
Upload your medical records and ask Navis questions tailored to your diagnosis.